A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

Study Summary

The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.

Conditions

Metastatic Solid Tumors

Interventions / Drugs

ERAS-4001 ERAS-4001 in combination

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment200 participants

Primary Completion—

Lead SponsorErasca, Inc.

Data Retrieved2026-04-11 04:13:01.654262+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.